The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

British Journal of Haematology

Volumn 171, Issue 2, 2015, Pages 215-226

  Marchi, Enrica ^a   Zullo, Kelly M ^a   Amengual, Jennifer E ^a   Kalac, Matko ^a   Bongero, Danielle ^a   Mcintosh, Christine M ^a   Fogli, Laura K ^c   Rossi, Maura ^b   Zinzani, Pier L ^b   Pileri, Stefano A ^b   Piccaluga, Pier P ^b   Fuligni, Fabio ^b   Scotto, Luigi ^a   O'Connor, Owen A ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epigenetic therapy; HDAC inhibitors; Hypomethylating agents; Preclinical models; T Cell Lymphoma

Indexed keywords

AZACITIDINE; BELINOSTAT; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; ROMIDEPSIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG POTENTIATION; GENE EXPRESSION; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; T-CELL LYMPHOMA CELL LINE; TUMOR XENOGRAFT;

EID: 84942987372     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13566     Document Type: Article

References (33)

1. Amengual, J.E., Clark-Garvey, S., Kalac, M., Scotto, L., Marchi, E., Neylon, E., Johannet, P., Wei, Y., Zain, J. & O'Connor, O.A. (2013) Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood, 122, 2104-2113.
2. Bates, S.E., Zhan, Z., Steadman, K., Obrzut, T., Luchenko, V., Frye, R., Robey, R.W., Turner, M., Gardner, E.R., Figg, W.D., Steinberg, S.M., Ling, A., Fojo, T., To, K.W. & Piekarz, R.L. (2010) Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. British Journal of Haematology, 148, 256-267.
3. Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological), 57, 289-300.
4. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., Ansorge, W., Ball, C.A., Causton, H.C., Gaasterland, T., Glenisson, P., Holstege, F.C., Kim, I.F., Markowitz, V., Matese, J.C., Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J., Taylor, R., Vilo, J. & Vingron, M. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nature Genetics, 29, 365-371.
5. Coiffier, B., Pro, B., Prince, H.M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., Pinter-Brown, L., Padmanabhan, S., Shustov, A., Nichols, J., Carroll, S., Balser, J., Balser, B. & Horwitz, S. (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology, 30, 631-636.
6. Deng, C., Pan, B. & O'Connor, O.A. (2013) Brentuximab vedotin. Clinical Cancer Research, 19, 22-27.
7. Duvic, M., Olsen, E.A., Breneman, D., Pacheco, T.R., Parker, S., Vonderheid, E.C., Abuav, R., Ricker, J.L., Rizvi, S., Chen, C., Boileau, K., Gunchenko, A., Sanz-Rodriguez, C. & Geskin, L.J. (2009) Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clinical Lymphoma Myeloma and Leukemia, 9, 412-416.
8. Edgar, R., Domrachev, M. & Lash, A.E. (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research, 30, 207-210.
9. Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proceedings of National Academy of Science of The United States of America, 95, 14863-14868.
10. Hartigan, J.A. (1975) Clustering algorithms. In: Clustering Algorithms (ed. by John Wiley & Sons, I.), pp. 351. John Wiley & sons, New York, NY.
11. Hosack, D.A., Dennis, G. Jr, Sherman, B.T., Lane, H.C. & Lempicki, R.A. (2003) Identifying biological themes within lists of genes with EASE. Genome Biology, 4, R70.
12. Huang da, W., Sherman, B.T. & Lempicki, R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4, 44-57.
13. Jenssen, T.K., Laegreid, A., Komorowski, J. & Hovig, E. (2001) A literature network of human genes for high-throughput analysis of gene expression. Nature Genetics, 28, 21-28.
14. Kalac, M., Scotto, L., Marchi, E., Amengual, J., Seshan, V.E., Bhagat, G., Ulahannan, N., Leshchenko, V.V., Temkin, A.M., Parekh, S., Tycko, B. & O'Connor, O.A. (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood, 118, 5506-5516.
15. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P.A., Scher, H. & Richon, V.M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23, 3923-3931.
16. Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L.H., Villa, D., Gascoyne, R.D., Connors, J.M. & Savage, K.J. (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Journal of Clinical Oncology, 31, 1970-1976.
17. Marchi, E., Paoluzzi, L., Scotto, L., Seshan, V.E., Zain, J.M., Zinzani, P.L. & O'Connor, O.A. (2010) Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clinical Cancer Research, 16, 3648-3658.
18. O'Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., Zelenetz, A.D., Frankel, S., Richon, V., Marks, P. & Kelly, W.K. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 24, 166-173.
19. O'Connor, O.A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Lechowicz, M.J., Savage, K.J., Shustov, A.R., Gisselbrecht, C., Jacobsen, E., Zinzani, P.L., Furman, R., Goy, A., Haioun, C., Crump, M., Zain, J.M., Hsi, E., Boyd, A. & Horwitz, S. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of Clinical Oncology, 29, 1182-1189.
20. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. & Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
21. Paoluzzi, L., Gonen, M., Gardner, J.R., Mastrella, J., Yang, D., Holmlund, J., Sorensen, M., Leopold, L., Manova, K., Marcucci, G., Heaney, M.L. & O'Connor, O.A. (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 111, 5350-5358.
22. Paoluzzi, L., Scotto, L., Marchi, E., Zain, J., Seshan, V.E. & O'Connor, O.A. (2010) Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clinical Cancer Research, 16, 554-565.
23. Piccaluga, P.P., Agostinelli, C., Califano, A., Carbone, A., Fantoni, L., Ferrari, S., Gazzola, A., Gloghini, A., Righi, S., Rossi, M., Tagliafico, E., Zinzani, P.L., Zupo, S., Baccarani, M. & Pileri, S.A. (2007a) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Research, 67, 10703-10710.
24. Piccaluga, P.P., Agostinelli, C., Califano, A., Rossi, M., Basso, K., Zupo, S., Went, P., Klein, U., Zinzani, P.L., Baccarani, M., Dalla Favera, R. & Pileri, S.A. (2007b) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. Journal of Clinical Investigation, 117, 823-834.
25. Piccaluga, P.P., Califano, A., Klein, U., Agostinelli, C., Bellosillo, B., Gimeno, E., Serrano, S., Sole, F., Zang, Y., Falini, B., Zinzani, P.L. & Pileri, S.A. (2008) Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica, 93, 1033-1038.
26. Piccaluga, P.P., De Falco, G., Kustagi, M., Gazzola, A., Agostinelli, C., Tripodo, C., Leucci, E., Onnis, A., Astolfi, A., Sapienza, M.R., Bellan, C., Lazzi, S., Tumwine, L., Mawanda, M., Ogwang, M., Calbi, V., Formica, S., Califano, A., Pileri, S.A. & Leoncini, L. (2011) Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood, 117, 3596-3608.
27. Piccaluga, P.P., Fuligni, F., De Leo, A., Bertuzzi, C., Rossi, M., Bacci, F., Sabattini, E., Agostinelli, C., Gazzola, A., Laginestra, M.A., Mannu, C., Sapienza, M.R., Hartmann, S., Hansmann, M.L., Piva, R., Iqbal, J., Chan, J.C., Weisenburger, D., Vose, J.M., Bellei, M., Federico, M., Inghirami, G., Zinzani, P.L. & Pileri, S.A. (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. Journal of Clinical Oncology, 31, 3019-3025.
28. Senter, P.D. & Sievers, E.L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 30, 631-637.
29. Smyth, G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology, 3, 1-25. No. 1, Article 3.
30. Toner, L.E., Vrhovac, R., Smith, E.A., Gardner, J., Heaney, M., Gonen, M., Teruya-Feldstein, J., Sirotnak, F. & O'Connor, O.A. (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clinical Cancer Research, 12, 924-932.
31. Wang, D., Yan, L., Hu, Q., Sucheston, L.E., Higgins, M.J., Ambrosone, C.B., Johnson, C.S., Smiraglia, D.J. & Liu, S. (2012) IMA: an R package for high-throughput analysis of Illumina's 450K infinium methylation data. Bioinformatics, 28, 729-730.
32. Zain, J.M. & O'Connor, O. (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. International Journal of Hematology, 92, 33-44.
33. Zain, J., Kaminetzky, D. & O'Connor, O.A. (2010) Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Review of Hematology, 3, 187-203.